Clinical Trial Update: A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients [Phase 3]

View source ↗

Summary

Phase III clinical study of KW-2246 for breakthrough pain in cancer patients completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Pain

Drugs mentioned

• KW-2246

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Pain, Cancer | Phase 3 | Status: COMPLETED